Former Medtronic Executive Michael Coyle Joins BaroPace Board

BaroPace Inc. has appointed former Medtronic executive Michael Coyle to its Board of Directors.

Coyle brings decades of experience in corporate leadership and the development and commercialization of innovative cardiovascular technologies to his new board role.
 
“Michael Coyle is one of the world’s most innovative thinkers and leaders in cardiovascular-related medical device technology,” said Michael Burnam, M.D., founder and CEO of BaroPace Inc. “He has a decades-long track record of discovering, nurturing, and developing cutting-edge technologies that save lives and advance the business interests of the biotechnology companies he’s led and advised. His leadership will help propel BaroPace to the next iteration of cardiac pacing and usher in an era of treatment for millions of patients with drug-resistant hypertension and HFpEF.”
 
Coyle served as executive vice president and president of the Cardiovascular portfolio at Medtronic from December 2009 to December 2020. He was responsible for optimizing Medtronic enterprise performance by supporting capital allocation, talent management, investments, and collaboration to create value across Medtronic’s cardiovascular-related operating units. Previously, he provided leadership consulting services to private equity, venture capital, and medical device technology firms. From 2001 to 2007, he served as divisional president at St. Jude Medical Inc. and led its global pacemaker, implantable cardioverter defibrillator, and cardiac resynchronization businesses. Coyle also led St. Jude’s Daig Catheter division and held leadership positions at Eli Lilly & Company. From January 2021 until June 2021, Coyle was CEO of iRhythm Technologies Inc.
 
“Hypertension is a very common comorbidity in patients requiring cardiac pacing,” said Coyle. “I believe BaroPace has identified and developed compelling technology and early clinical evidence as to how their proprietary pacing algorithms can potentially address treatment resistant hypertension and potentially improve clinical outcomes pending completion of technology development and regulatory approval of these promising technologies. I am very pleased to join the company’s Board and assist them in their work.”
 
BaroPace is a research and development company with proprietary biotechnologies including a pacemaker control algorithm (PressurePace) and new sensor technologies working through patient mobile and wearable platforms. BaroPace expects to launch a first-in-human clinical trial (RelieveHTN-I) in the fourth quarter this year.